nodes	percent_of_prediction	percent_of_DWPC	metapath
Cyclophosphamide—ABCB1—colon cancer	0.311	1	CbGaD
Cyclophosphamide—CYP2A6—Fluorouracil—colon cancer	0.0597	0.125	CbGbCtD
Cyclophosphamide—CYP3A7—Irinotecan—colon cancer	0.0425	0.0891	CbGbCtD
Cyclophosphamide—CYP3A7-CYP3A51P—Irinotecan—colon cancer	0.0425	0.0891	CbGbCtD
Cyclophosphamide—CYP2B6—Irinotecan—colon cancer	0.0405	0.0849	CbGbCtD
Cyclophosphamide—CYP3A7—Vincristine—colon cancer	0.0371	0.0779	CbGbCtD
Cyclophosphamide—CYP3A7-CYP3A51P—Vincristine—colon cancer	0.0371	0.0779	CbGbCtD
Cyclophosphamide—CYP2C9—Capecitabine—colon cancer	0.0346	0.0726	CbGbCtD
Cyclophosphamide—CYP3A5—Irinotecan—colon cancer	0.0319	0.0669	CbGbCtD
Cyclophosphamide—CYP2C8—Fluorouracil—colon cancer	0.0294	0.0617	CbGbCtD
Cyclophosphamide—CYP3A5—Vincristine—colon cancer	0.0279	0.0584	CbGbCtD
Cyclophosphamide—ABCB1—Irinotecan—colon cancer	0.0207	0.0435	CbGbCtD
Cyclophosphamide—CYP2C9—Fluorouracil—colon cancer	0.0205	0.043	CbGbCtD
Cyclophosphamide—ABCB1—Vincristine—colon cancer	0.0181	0.038	CbGbCtD
Cyclophosphamide—CYP3A4—Irinotecan—colon cancer	0.0124	0.0261	CbGbCtD
Cyclophosphamide—ABCB1—Methotrexate—colon cancer	0.011	0.023	CbGbCtD
Cyclophosphamide—CYP3A4—Vincristine—colon cancer	0.0109	0.0228	CbGbCtD
Cyclophosphamide—Haemorrhage—Fluorouracil—colon cancer	0.000249	0.00119	CcSEcCtD
Cyclophosphamide—Hypoaesthesia—Fluorouracil—colon cancer	0.000248	0.00118	CcSEcCtD
Cyclophosphamide—Flushing—Irinotecan—colon cancer	0.000241	0.00115	CcSEcCtD
Cyclophosphamide—Cardiac arrest—Capecitabine—colon cancer	0.000239	0.00114	CcSEcCtD
Cyclophosphamide—Alopecia—Vincristine—colon cancer	0.000236	0.00112	CcSEcCtD
Cyclophosphamide—Chills—Irinotecan—colon cancer	0.000233	0.00111	CcSEcCtD
Cyclophosphamide—Bladder pain—Methotrexate—colon cancer	0.000233	0.00111	CcSEcCtD
Cyclophosphamide—Neoplasm—Methotrexate—colon cancer	0.000233	0.00111	CcSEcCtD
Cyclophosphamide—Mouth ulceration—Methotrexate—colon cancer	0.000233	0.00111	CcSEcCtD
Cyclophosphamide—Arrhythmia—Irinotecan—colon cancer	0.000232	0.00111	CcSEcCtD
Cyclophosphamide—Alopecia—Irinotecan—colon cancer	0.00023	0.0011	CcSEcCtD
Cyclophosphamide—Pulmonary oedema—Methotrexate—colon cancer	0.00023	0.00109	CcSEcCtD
Cyclophosphamide—Toxic epidermal necrolysis—Capecitabine—colon cancer	0.000226	0.00108	CcSEcCtD
Cyclophosphamide—Nasopharyngitis—Capecitabine—colon cancer	0.000225	0.00107	CcSEcCtD
Cyclophosphamide—Sepsis—Methotrexate—colon cancer	0.000224	0.00107	CcSEcCtD
Cyclophosphamide—Arrhythmia—Fluorouracil—colon cancer	0.000222	0.00106	CcSEcCtD
Cyclophosphamide—Alopecia—Fluorouracil—colon cancer	0.00022	0.00105	CcSEcCtD
Cyclophosphamide—Muscle spasms—Irinotecan—colon cancer	0.000218	0.00104	CcSEcCtD
Cyclophosphamide—Erythema—Fluorouracil—colon cancer	0.000217	0.00103	CcSEcCtD
Cyclophosphamide—Diabetes mellitus—Methotrexate—colon cancer	0.000215	0.00103	CcSEcCtD
Cyclophosphamide—Anaemia—Vincristine—colon cancer	0.000215	0.00102	CcSEcCtD
Cyclophosphamide—Bronchospasm—Capecitabine—colon cancer	0.000214	0.00102	CcSEcCtD
Cyclophosphamide—Agitation—Vincristine—colon cancer	0.000214	0.00102	CcSEcCtD
Cyclophosphamide—Polyuria—Methotrexate—colon cancer	0.000213	0.00102	CcSEcCtD
Cyclophosphamide—Sweating increased—Capecitabine—colon cancer	0.000212	0.00101	CcSEcCtD
Cyclophosphamide—Ill-defined disorder—Irinotecan—colon cancer	0.00021	0.001	CcSEcCtD
Cyclophosphamide—Anaemia—Irinotecan—colon cancer	0.000209	0.000997	CcSEcCtD
Cyclophosphamide—Abdominal discomfort—Capecitabine—colon cancer	0.000208	0.000994	CcSEcCtD
Cyclophosphamide—Hepatic failure—Methotrexate—colon cancer	0.000208	0.000993	CcSEcCtD
Cyclophosphamide—Leukopenia—Vincristine—colon cancer	0.000208	0.000992	CcSEcCtD
Cyclophosphamide—Pancytopenia—Capecitabine—colon cancer	0.000206	0.000984	CcSEcCtD
Cyclophosphamide—Vision blurred—Fluorouracil—colon cancer	0.000204	0.000974	CcSEcCtD
Cyclophosphamide—Malaise—Irinotecan—colon cancer	0.000204	0.000973	CcSEcCtD
Cyclophosphamide—Renal failure acute—Methotrexate—colon cancer	0.000203	0.000967	CcSEcCtD
Cyclophosphamide—Leukopenia—Irinotecan—colon cancer	0.000203	0.000966	CcSEcCtD
Cyclophosphamide—Convulsion—Vincristine—colon cancer	0.000201	0.00096	CcSEcCtD
Cyclophosphamide—Hypertension—Vincristine—colon cancer	0.000201	0.000957	CcSEcCtD
Cyclophosphamide—Anaemia—Fluorouracil—colon cancer	0.0002	0.000955	CcSEcCtD
Cyclophosphamide—Myalgia—Vincristine—colon cancer	0.000198	0.000943	CcSEcCtD
Cyclophosphamide—Weight increased—Capecitabine—colon cancer	0.000198	0.000943	CcSEcCtD
Cyclophosphamide—Cough—Irinotecan—colon cancer	0.000197	0.000942	CcSEcCtD
Cyclophosphamide—Hyperglycaemia—Capecitabine—colon cancer	0.000196	0.000935	CcSEcCtD
Cyclophosphamide—Hypertension—Irinotecan—colon cancer	0.000195	0.000932	CcSEcCtD
Cyclophosphamide—Pneumonia—Capecitabine—colon cancer	0.000195	0.00093	CcSEcCtD
Cyclophosphamide—Leukopenia—Fluorouracil—colon cancer	0.000194	0.000925	CcSEcCtD
Cyclophosphamide—Stevens-Johnson syndrome—Capecitabine—colon cancer	0.000192	0.000916	CcSEcCtD
Cyclophosphamide—Acute coronary syndrome—Capecitabine—colon cancer	0.000191	0.000911	CcSEcCtD
Cyclophosphamide—Renal failure—Capecitabine—colon cancer	0.000191	0.000908	CcSEcCtD
Cyclophosphamide—Discomfort—Irinotecan—colon cancer	0.00019	0.000908	CcSEcCtD
Cyclophosphamide—Myocardial infarction—Capecitabine—colon cancer	0.00019	0.000906	CcSEcCtD
Cyclophosphamide—Neuropathy peripheral—Capecitabine—colon cancer	0.00019	0.000906	CcSEcCtD
Cyclophosphamide—Oedema—Vincristine—colon cancer	0.00019	0.000904	CcSEcCtD
Cyclophosphamide—Anaphylactic shock—Vincristine—colon cancer	0.00019	0.000904	CcSEcCtD
Cyclophosphamide—Jaundice—Capecitabine—colon cancer	0.000189	0.000901	CcSEcCtD
Cyclophosphamide—Stomatitis—Capecitabine—colon cancer	0.000189	0.000901	CcSEcCtD
Cyclophosphamide—Infection—Vincristine—colon cancer	0.000188	0.000898	CcSEcCtD
Cyclophosphamide—Conjunctivitis—Capecitabine—colon cancer	0.000188	0.000898	CcSEcCtD
Cyclophosphamide—Convulsion—Fluorouracil—colon cancer	0.000188	0.000895	CcSEcCtD
Cyclophosphamide—Confusional state—Irinotecan—colon cancer	0.000186	0.000888	CcSEcCtD
Cyclophosphamide—Thrombocytopenia—Vincristine—colon cancer	0.000186	0.000885	CcSEcCtD
Cyclophosphamide—Haematuria—Capecitabine—colon cancer	0.000185	0.000881	CcSEcCtD
Cyclophosphamide—Oedema—Irinotecan—colon cancer	0.000185	0.000881	CcSEcCtD
Cyclophosphamide—Anaphylactic shock—Irinotecan—colon cancer	0.000185	0.000881	CcSEcCtD
Cyclophosphamide—Chest pain—Fluorouracil—colon cancer	0.000185	0.00088	CcSEcCtD
Cyclophosphamide—Myalgia—Fluorouracil—colon cancer	0.000185	0.00088	CcSEcCtD
Cyclophosphamide—Infection—Irinotecan—colon cancer	0.000183	0.000875	CcSEcCtD
Cyclophosphamide—Hyperhidrosis—Vincristine—colon cancer	0.000183	0.000874	CcSEcCtD
Cyclophosphamide—Discomfort—Fluorouracil—colon cancer	0.000182	0.000869	CcSEcCtD
Cyclophosphamide—Shock—Irinotecan—colon cancer	0.000182	0.000866	CcSEcCtD
Cyclophosphamide—Agranulocytosis—Capecitabine—colon cancer	0.000181	0.000862	CcSEcCtD
Cyclophosphamide—Thrombocytopenia—Irinotecan—colon cancer	0.000181	0.000862	CcSEcCtD
Cyclophosphamide—CYP2C18—digestive system—colon cancer	0.000181	0.07	CbGeAlD
Cyclophosphamide—Anorexia—Vincristine—colon cancer	0.000181	0.000862	CcSEcCtD
Cyclophosphamide—Hyperhidrosis—Irinotecan—colon cancer	0.000179	0.000851	CcSEcCtD
Cyclophosphamide—Confusional state—Fluorouracil—colon cancer	0.000178	0.00085	CcSEcCtD
Cyclophosphamide—Hypotension—Vincristine—colon cancer	0.000177	0.000845	CcSEcCtD
Cyclophosphamide—Bradycardia—Capecitabine—colon cancer	0.000177	0.000845	CcSEcCtD
Cyclophosphamide—Anaphylactic shock—Fluorouracil—colon cancer	0.000177	0.000843	CcSEcCtD
Cyclophosphamide—Oedema—Fluorouracil—colon cancer	0.000177	0.000843	CcSEcCtD
Cyclophosphamide—Anorexia—Irinotecan—colon cancer	0.000176	0.000839	CcSEcCtD
Cyclophosphamide—Infection—Fluorouracil—colon cancer	0.000176	0.000838	CcSEcCtD
Cyclophosphamide—Haemoglobin—Capecitabine—colon cancer	0.000175	0.000834	CcSEcCtD
Cyclophosphamide—Rhinitis—Capecitabine—colon cancer	0.000174	0.000832	CcSEcCtD
Cyclophosphamide—Haemorrhage—Capecitabine—colon cancer	0.000174	0.00083	CcSEcCtD
Cyclophosphamide—Hepatitis—Capecitabine—colon cancer	0.000174	0.00083	CcSEcCtD
Cyclophosphamide—Thrombocytopenia—Fluorouracil—colon cancer	0.000173	0.000826	CcSEcCtD
Cyclophosphamide—Hypoaesthesia—Capecitabine—colon cancer	0.000173	0.000825	CcSEcCtD
Cyclophosphamide—Musculoskeletal discomfort—Vincristine—colon cancer	0.000173	0.000824	CcSEcCtD
Cyclophosphamide—Tachycardia—Fluorouracil—colon cancer	0.000173	0.000823	CcSEcCtD
Cyclophosphamide—Hypotension—Irinotecan—colon cancer	0.000173	0.000823	CcSEcCtD
Cyclophosphamide—Paraesthesia—Vincristine—colon cancer	0.00017	0.000812	CcSEcCtD
Cyclophosphamide—Anorexia—Fluorouracil—colon cancer	0.000169	0.000804	CcSEcCtD
Cyclophosphamide—Toxic epidermal necrolysis—Methotrexate—colon cancer	0.000169	0.000804	CcSEcCtD
Cyclophosphamide—Visual impairment—Capecitabine—colon cancer	0.000168	0.000799	CcSEcCtD
Cyclophosphamide—Paraesthesia—Irinotecan—colon cancer	0.000166	0.000791	CcSEcCtD
Cyclophosphamide—Hypotension—Fluorouracil—colon cancer	0.000165	0.000788	CcSEcCtD
Cyclophosphamide—Decreased appetite—Vincristine—colon cancer	0.000165	0.000786	CcSEcCtD
Cyclophosphamide—Dyspnoea—Irinotecan—colon cancer	0.000165	0.000785	CcSEcCtD
Cyclophosphamide—Erythema multiforme—Capecitabine—colon cancer	0.000165	0.000784	CcSEcCtD
Cyclophosphamide—Fatigue—Vincristine—colon cancer	0.000163	0.00078	CcSEcCtD
Cyclophosphamide—Tinnitus—Capecitabine—colon cancer	0.000162	0.000774	CcSEcCtD
Cyclophosphamide—Constipation—Vincristine—colon cancer	0.000162	0.000773	CcSEcCtD
Cyclophosphamide—Pain—Vincristine—colon cancer	0.000162	0.000773	CcSEcCtD
Cyclophosphamide—Flushing—Capecitabine—colon cancer	0.000161	0.00077	CcSEcCtD
Cyclophosphamide—Musculoskeletal discomfort—Fluorouracil—colon cancer	0.000161	0.000768	CcSEcCtD
Cyclophosphamide—Decreased appetite—Irinotecan—colon cancer	0.000161	0.000766	CcSEcCtD
Cyclophosphamide—CYP2C18—vagina—colon cancer	0.00016	0.0618	CbGeAlD
Cyclophosphamide—Fatigue—Irinotecan—colon cancer	0.000159	0.000759	CcSEcCtD
Cyclophosphamide—Paraesthesia—Fluorouracil—colon cancer	0.000159	0.000757	CcSEcCtD
Cyclophosphamide—Constipation—Irinotecan—colon cancer	0.000158	0.000753	CcSEcCtD
Cyclophosphamide—Pain—Irinotecan—colon cancer	0.000158	0.000753	CcSEcCtD
Cyclophosphamide—Dyspnoea—Fluorouracil—colon cancer	0.000158	0.000752	CcSEcCtD
Cyclophosphamide—Chills—Capecitabine—colon cancer	0.000156	0.000744	CcSEcCtD
Cyclophosphamide—Arrhythmia—Capecitabine—colon cancer	0.000155	0.000741	CcSEcCtD
Cyclophosphamide—Abdominal discomfort—Methotrexate—colon cancer	0.000155	0.00074	CcSEcCtD
Cyclophosphamide—Decreased appetite—Fluorouracil—colon cancer	0.000154	0.000733	CcSEcCtD
Cyclophosphamide—Alopecia—Capecitabine—colon cancer	0.000154	0.000733	CcSEcCtD
Cyclophosphamide—Pancytopenia—Methotrexate—colon cancer	0.000154	0.000733	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Irinotecan—colon cancer	0.000152	0.000726	CcSEcCtD
Cyclophosphamide—Erythema—Capecitabine—colon cancer	0.000151	0.000722	CcSEcCtD
Cyclophosphamide—Pain—Fluorouracil—colon cancer	0.000151	0.000721	CcSEcCtD
Cyclophosphamide—Body temperature increased—Vincristine—colon cancer	0.00015	0.000715	CcSEcCtD
Cyclophosphamide—Dysgeusia—Capecitabine—colon cancer	0.000148	0.000707	CcSEcCtD
Cyclophosphamide—Body temperature increased—Irinotecan—colon cancer	0.000146	0.000696	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Fluorouracil—colon cancer	0.000146	0.000695	CcSEcCtD
Cyclophosphamide—Muscle spasms—Capecitabine—colon cancer	0.000146	0.000694	CcSEcCtD
Cyclophosphamide—Pneumonia—Methotrexate—colon cancer	0.000145	0.000692	CcSEcCtD
Cyclophosphamide—Stevens-Johnson syndrome—Methotrexate—colon cancer	0.000143	0.000682	CcSEcCtD
Cyclophosphamide—Vision blurred—Capecitabine—colon cancer	0.000143	0.000681	CcSEcCtD
Cyclophosphamide—Tremor—Capecitabine—colon cancer	0.000142	0.000677	CcSEcCtD
Cyclophosphamide—Renal failure—Methotrexate—colon cancer	0.000142	0.000676	CcSEcCtD
Cyclophosphamide—Stomatitis—Methotrexate—colon cancer	0.000141	0.000671	CcSEcCtD
Cyclophosphamide—Ill-defined disorder—Capecitabine—colon cancer	0.000141	0.00067	CcSEcCtD
Cyclophosphamide—Urticaria—Fluorouracil—colon cancer	0.000141	0.00067	CcSEcCtD
Cyclophosphamide—Conjunctivitis—Methotrexate—colon cancer	0.00014	0.000669	CcSEcCtD
Cyclophosphamide—Anaemia—Capecitabine—colon cancer	0.00014	0.000667	CcSEcCtD
Cyclophosphamide—Body temperature increased—Fluorouracil—colon cancer	0.00014	0.000667	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Vincristine—colon cancer	0.00014	0.000666	CcSEcCtD
Cyclophosphamide—Sweating—Methotrexate—colon cancer	0.000138	0.00066	CcSEcCtD
Cyclophosphamide—Haematuria—Methotrexate—colon cancer	0.000138	0.000656	CcSEcCtD
Cyclophosphamide—Malaise—Capecitabine—colon cancer	0.000137	0.000651	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Irinotecan—colon cancer	0.000136	0.000649	CcSEcCtD
Cyclophosphamide—Asthenia—Vincristine—colon cancer	0.000136	0.000649	CcSEcCtD
Cyclophosphamide—Leukopenia—Capecitabine—colon cancer	0.000136	0.000646	CcSEcCtD
Cyclophosphamide—CYP2C18—liver—colon cancer	0.000135	0.0522	CbGeAlD
Cyclophosphamide—Agranulocytosis—Methotrexate—colon cancer	0.000135	0.000642	CcSEcCtD
Cyclophosphamide—Palpitations—Capecitabine—colon cancer	0.000134	0.000638	CcSEcCtD
Cyclophosphamide—Asthenia—Irinotecan—colon cancer	0.000133	0.000632	CcSEcCtD
Cyclophosphamide—Cough—Capecitabine—colon cancer	0.000132	0.00063	CcSEcCtD
Cyclophosphamide—Hypertension—Capecitabine—colon cancer	0.000131	0.000624	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Fluorouracil—colon cancer	0.00013	0.000621	CcSEcCtD
Cyclophosphamide—Haemoglobin—Methotrexate—colon cancer	0.00013	0.000621	CcSEcCtD
Cyclophosphamide—Diarrhoea—Vincristine—colon cancer	0.00013	0.000619	CcSEcCtD
Cyclophosphamide—Haemorrhage—Methotrexate—colon cancer	0.00013	0.000618	CcSEcCtD
Cyclophosphamide—Hepatitis—Methotrexate—colon cancer	0.00013	0.000618	CcSEcCtD
Cyclophosphamide—Chest pain—Capecitabine—colon cancer	0.000129	0.000615	CcSEcCtD
Cyclophosphamide—Arthralgia—Capecitabine—colon cancer	0.000129	0.000615	CcSEcCtD
Cyclophosphamide—Myalgia—Capecitabine—colon cancer	0.000129	0.000615	CcSEcCtD
Cyclophosphamide—CYP3A7—liver—colon cancer	0.000128	0.0496	CbGeAlD
Cyclophosphamide—Discomfort—Capecitabine—colon cancer	0.000127	0.000607	CcSEcCtD
Cyclophosphamide—Diarrhoea—Irinotecan—colon cancer	0.000126	0.000603	CcSEcCtD
Cyclophosphamide—Dizziness—Vincristine—colon cancer	0.000125	0.000598	CcSEcCtD
Cyclophosphamide—Pruritus—Fluorouracil—colon cancer	0.000125	0.000597	CcSEcCtD
Cyclophosphamide—Visual impairment—Methotrexate—colon cancer	0.000125	0.000595	CcSEcCtD
Cyclophosphamide—Confusional state—Capecitabine—colon cancer	0.000125	0.000594	CcSEcCtD
Cyclophosphamide—Oedema—Capecitabine—colon cancer	0.000124	0.000589	CcSEcCtD
Cyclophosphamide—Infection—Capecitabine—colon cancer	0.000123	0.000586	CcSEcCtD
Cyclophosphamide—Erythema multiforme—Methotrexate—colon cancer	0.000122	0.000584	CcSEcCtD
Cyclophosphamide—Dizziness—Irinotecan—colon cancer	0.000122	0.000582	CcSEcCtD
Cyclophosphamide—Shock—Capecitabine—colon cancer	0.000122	0.00058	CcSEcCtD
Cyclophosphamide—Diarrhoea—Fluorouracil—colon cancer	0.000121	0.000577	CcSEcCtD
Cyclophosphamide—Thrombocytopenia—Capecitabine—colon cancer	0.000121	0.000577	CcSEcCtD
Cyclophosphamide—Tinnitus—Methotrexate—colon cancer	0.000121	0.000576	CcSEcCtD
Cyclophosphamide—Tachycardia—Capecitabine—colon cancer	0.000121	0.000575	CcSEcCtD
Cyclophosphamide—Vomiting—Vincristine—colon cancer	0.000121	0.000575	CcSEcCtD
Cyclophosphamide—Rash—Vincristine—colon cancer	0.00012	0.00057	CcSEcCtD
Cyclophosphamide—Hyperhidrosis—Capecitabine—colon cancer	0.000119	0.00057	CcSEcCtD
Cyclophosphamide—Dermatitis—Vincristine—colon cancer	0.000119	0.00057	CcSEcCtD
Cyclophosphamide—Headache—Vincristine—colon cancer	0.000119	0.000566	CcSEcCtD
Cyclophosphamide—Anorexia—Capecitabine—colon cancer	0.000118	0.000562	CcSEcCtD
Cyclophosphamide—Vomiting—Irinotecan—colon cancer	0.000117	0.00056	CcSEcCtD
Cyclophosphamide—Dizziness—Fluorouracil—colon cancer	0.000117	0.000558	CcSEcCtD
Cyclophosphamide—Rash—Irinotecan—colon cancer	0.000116	0.000555	CcSEcCtD
Cyclophosphamide—Dermatitis—Irinotecan—colon cancer	0.000116	0.000555	CcSEcCtD
Cyclophosphamide—Chills—Methotrexate—colon cancer	0.000116	0.000554	CcSEcCtD
Cyclophosphamide—Headache—Irinotecan—colon cancer	0.000116	0.000552	CcSEcCtD
Cyclophosphamide—Hypotension—Capecitabine—colon cancer	0.000116	0.000551	CcSEcCtD
Cyclophosphamide—Alopecia—Methotrexate—colon cancer	0.000114	0.000546	CcSEcCtD
Cyclophosphamide—Erythema—Methotrexate—colon cancer	0.000113	0.000538	CcSEcCtD
Cyclophosphamide—Nausea—Vincristine—colon cancer	0.000113	0.000537	CcSEcCtD
Cyclophosphamide—Musculoskeletal discomfort—Capecitabine—colon cancer	0.000113	0.000537	CcSEcCtD
Cyclophosphamide—Vomiting—Fluorouracil—colon cancer	0.000112	0.000536	CcSEcCtD
Cyclophosphamide—Rash—Fluorouracil—colon cancer	0.000112	0.000532	CcSEcCtD
Cyclophosphamide—Dermatitis—Fluorouracil—colon cancer	0.000111	0.000531	CcSEcCtD
Cyclophosphamide—Paraesthesia—Capecitabine—colon cancer	0.000111	0.000529	CcSEcCtD
Cyclophosphamide—Headache—Fluorouracil—colon cancer	0.000111	0.000528	CcSEcCtD
Cyclophosphamide—Dysgeusia—Methotrexate—colon cancer	0.00011	0.000526	CcSEcCtD
Cyclophosphamide—Dyspnoea—Capecitabine—colon cancer	0.00011	0.000525	CcSEcCtD
Cyclophosphamide—Nausea—Irinotecan—colon cancer	0.00011	0.000523	CcSEcCtD
Cyclophosphamide—CYP3A7-CYP3A51P—liver—colon cancer	0.000109	0.0422	CbGeAlD
Cyclophosphamide—Decreased appetite—Capecitabine—colon cancer	0.000107	0.000512	CcSEcCtD
Cyclophosphamide—Fatigue—Capecitabine—colon cancer	0.000107	0.000508	CcSEcCtD
Cyclophosphamide—Vision blurred—Methotrexate—colon cancer	0.000106	0.000507	CcSEcCtD
Cyclophosphamide—Constipation—Capecitabine—colon cancer	0.000106	0.000504	CcSEcCtD
Cyclophosphamide—Pain—Capecitabine—colon cancer	0.000106	0.000504	CcSEcCtD
Cyclophosphamide—CYP2A6—vagina—colon cancer	0.000105	0.0409	CbGeAlD
Cyclophosphamide—Nausea—Fluorouracil—colon cancer	0.000105	0.000501	CcSEcCtD
Cyclophosphamide—Ill-defined disorder—Methotrexate—colon cancer	0.000105	0.000499	CcSEcCtD
Cyclophosphamide—Anaemia—Methotrexate—colon cancer	0.000104	0.000497	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Capecitabine—colon cancer	0.000102	0.000486	CcSEcCtD
Cyclophosphamide—Malaise—Methotrexate—colon cancer	0.000102	0.000485	CcSEcCtD
Cyclophosphamide—Leukopenia—Methotrexate—colon cancer	0.000101	0.000481	CcSEcCtD
Cyclophosphamide—Cough—Methotrexate—colon cancer	9.84e-05	0.000469	CcSEcCtD
Cyclophosphamide—Urticaria—Capecitabine—colon cancer	9.82e-05	0.000468	CcSEcCtD
Cyclophosphamide—Body temperature increased—Capecitabine—colon cancer	9.77e-05	0.000466	CcSEcCtD
Cyclophosphamide—Convulsion—Methotrexate—colon cancer	9.77e-05	0.000466	CcSEcCtD
Cyclophosphamide—Chest pain—Methotrexate—colon cancer	9.6e-05	0.000458	CcSEcCtD
Cyclophosphamide—Arthralgia—Methotrexate—colon cancer	9.6e-05	0.000458	CcSEcCtD
Cyclophosphamide—Myalgia—Methotrexate—colon cancer	9.6e-05	0.000458	CcSEcCtD
Cyclophosphamide—Discomfort—Methotrexate—colon cancer	9.48e-05	0.000452	CcSEcCtD
Cyclophosphamide—Confusional state—Methotrexate—colon cancer	9.28e-05	0.000442	CcSEcCtD
Cyclophosphamide—Anaphylactic shock—Methotrexate—colon cancer	9.2e-05	0.000439	CcSEcCtD
Cyclophosphamide—Infection—Methotrexate—colon cancer	9.14e-05	0.000436	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Capecitabine—colon cancer	9.11e-05	0.000434	CcSEcCtD
Cyclophosphamide—Thrombocytopenia—Methotrexate—colon cancer	9.01e-05	0.00043	CcSEcCtD
Cyclophosphamide—CYP2A6—liver—colon cancer	8.9e-05	0.0345	CbGeAlD
Cyclophosphamide—Hyperhidrosis—Methotrexate—colon cancer	8.9e-05	0.000424	CcSEcCtD
Cyclophosphamide—Asthenia—Capecitabine—colon cancer	8.87e-05	0.000423	CcSEcCtD
Cyclophosphamide—Anorexia—Methotrexate—colon cancer	8.77e-05	0.000418	CcSEcCtD
Cyclophosphamide—Pruritus—Capecitabine—colon cancer	8.75e-05	0.000417	CcSEcCtD
Cyclophosphamide—ABCB1—blood vessel—colon cancer	8.68e-05	0.0336	CbGeAlD
Cyclophosphamide—Hypotension—Methotrexate—colon cancer	8.6e-05	0.00041	CcSEcCtD
Cyclophosphamide—Diarrhoea—Capecitabine—colon cancer	8.46e-05	0.000403	CcSEcCtD
Cyclophosphamide—Musculoskeletal discomfort—Methotrexate—colon cancer	8.38e-05	0.0004	CcSEcCtD
Cyclophosphamide—Paraesthesia—Methotrexate—colon cancer	8.26e-05	0.000394	CcSEcCtD
Cyclophosphamide—Dyspnoea—Methotrexate—colon cancer	8.2e-05	0.000391	CcSEcCtD
Cyclophosphamide—CYP2C8—renal system—colon cancer	8.18e-05	0.0317	CbGeAlD
Cyclophosphamide—Dizziness—Capecitabine—colon cancer	8.17e-05	0.00039	CcSEcCtD
Cyclophosphamide—Decreased appetite—Methotrexate—colon cancer	8e-05	0.000381	CcSEcCtD
Cyclophosphamide—Fatigue—Methotrexate—colon cancer	7.93e-05	0.000378	CcSEcCtD
Cyclophosphamide—Pain—Methotrexate—colon cancer	7.87e-05	0.000375	CcSEcCtD
Cyclophosphamide—Vomiting—Capecitabine—colon cancer	7.86e-05	0.000375	CcSEcCtD
Cyclophosphamide—Rash—Capecitabine—colon cancer	7.79e-05	0.000372	CcSEcCtD
Cyclophosphamide—Dermatitis—Capecitabine—colon cancer	7.79e-05	0.000371	CcSEcCtD
Cyclophosphamide—Headache—Capecitabine—colon cancer	7.74e-05	0.000369	CcSEcCtD
Cyclophosphamide—CYP2C19—digestive system—colon cancer	7.68e-05	0.0298	CbGeAlD
Cyclophosphamide—Feeling abnormal—Methotrexate—colon cancer	7.58e-05	0.000362	CcSEcCtD
Cyclophosphamide—CYP3A5—renal system—colon cancer	7.38e-05	0.0286	CbGeAlD
Cyclophosphamide—Nausea—Capecitabine—colon cancer	7.34e-05	0.00035	CcSEcCtD
Cyclophosphamide—CYP2B6—renal system—colon cancer	7.33e-05	0.0284	CbGeAlD
Cyclophosphamide—Urticaria—Methotrexate—colon cancer	7.31e-05	0.000349	CcSEcCtD
Cyclophosphamide—Body temperature increased—Methotrexate—colon cancer	7.27e-05	0.000347	CcSEcCtD
Cyclophosphamide—CYP2C19—vagina—colon cancer	6.79e-05	0.0263	CbGeAlD
Cyclophosphamide—Hypersensitivity—Methotrexate—colon cancer	6.78e-05	0.000323	CcSEcCtD
Cyclophosphamide—Asthenia—Methotrexate—colon cancer	6.6e-05	0.000315	CcSEcCtD
Cyclophosphamide—Pruritus—Methotrexate—colon cancer	6.51e-05	0.00031	CcSEcCtD
Cyclophosphamide—Diarrhoea—Methotrexate—colon cancer	6.3e-05	0.0003	CcSEcCtD
Cyclophosphamide—CYP2B6—lymphoid tissue—colon cancer	6.09e-05	0.0236	CbGeAlD
Cyclophosphamide—Dizziness—Methotrexate—colon cancer	6.08e-05	0.00029	CcSEcCtD
Cyclophosphamide—CYP3A5—digestive system—colon cancer	6.05e-05	0.0235	CbGeAlD
Cyclophosphamide—CYP2B6—digestive system—colon cancer	6.02e-05	0.0233	CbGeAlD
Cyclophosphamide—CYP2C9—digestive system—colon cancer	5.96e-05	0.0231	CbGeAlD
Cyclophosphamide—CYP2C8—vagina—colon cancer	5.92e-05	0.0229	CbGeAlD
Cyclophosphamide—Vomiting—Methotrexate—colon cancer	5.85e-05	0.000279	CcSEcCtD
Cyclophosphamide—Rash—Methotrexate—colon cancer	5.8e-05	0.000277	CcSEcCtD
Cyclophosphamide—Dermatitis—Methotrexate—colon cancer	5.8e-05	0.000276	CcSEcCtD
Cyclophosphamide—Headache—Methotrexate—colon cancer	5.76e-05	0.000275	CcSEcCtD
Cyclophosphamide—CYP2C19—liver—colon cancer	5.72e-05	0.0222	CbGeAlD
Cyclophosphamide—CYP3A4—renal system—colon cancer	5.54e-05	0.0215	CbGeAlD
Cyclophosphamide—Nausea—Methotrexate—colon cancer	5.47e-05	0.000261	CcSEcCtD
Cyclophosphamide—CYP2D6—renal system—colon cancer	5.45e-05	0.0211	CbGeAlD
Cyclophosphamide—CYP3A5—vagina—colon cancer	5.35e-05	0.0207	CbGeAlD
Cyclophosphamide—CYP2B6—vagina—colon cancer	5.31e-05	0.0206	CbGeAlD
Cyclophosphamide—ABCB1—embryo—colon cancer	5.18e-05	0.0201	CbGeAlD
Cyclophosphamide—CYP2C8—liver—colon cancer	5e-05	0.0194	CbGeAlD
Cyclophosphamide—CYP3A4—digestive system—colon cancer	4.54e-05	0.0176	CbGeAlD
Cyclophosphamide—CYP3A5—liver—colon cancer	4.51e-05	0.0175	CbGeAlD
Cyclophosphamide—CYP2B6—liver—colon cancer	4.48e-05	0.0174	CbGeAlD
Cyclophosphamide—CYP2D6—digestive system—colon cancer	4.47e-05	0.0173	CbGeAlD
Cyclophosphamide—CYP2C9—liver—colon cancer	4.44e-05	0.0172	CbGeAlD
Cyclophosphamide—ABCB1—epithelium—colon cancer	4.23e-05	0.0164	CbGeAlD
Cyclophosphamide—ABCB1—renal system—colon cancer	3.92e-05	0.0152	CbGeAlD
Cyclophosphamide—CYP3A4—liver—colon cancer	3.38e-05	0.0131	CbGeAlD
Cyclophosphamide—CYP2D6—liver—colon cancer	3.33e-05	0.0129	CbGeAlD
Cyclophosphamide—ABCB1—lymphoid tissue—colon cancer	3.26e-05	0.0126	CbGeAlD
Cyclophosphamide—ABCB1—digestive system—colon cancer	3.22e-05	0.0125	CbGeAlD
Cyclophosphamide—ABCB1—bone marrow—colon cancer	2.96e-05	0.0115	CbGeAlD
Cyclophosphamide—ABCB1—vagina—colon cancer	2.84e-05	0.011	CbGeAlD
Cyclophosphamide—ABCB1—liver—colon cancer	2.4e-05	0.00928	CbGeAlD
Cyclophosphamide—ABCB1—lymph node—colon cancer	1.84e-05	0.00712	CbGeAlD
